RESUMEN

Melasma is an acquired hyperpigmentation disease characterized by hyperpigmented patches in sun-exposed areas that significantly impairs life quality. Topical treatments such as hydroquinone, retinoic acid, azelaic acid, chemical peels and laser treatments are among the main treatment options. In our study, we aimed to compare the effectiveness of Jessner peeling and 1064 nm Q-switched Nd:YAG laser in melasma treatment. For this purpose, Jessner peeling was applied to 20 patients and 1064 nm Q-switched Nd: YAG laser was applied to 19 patients of 39 melasma patients who applied to the cosmetology unit of Ege University department of dermatology and venereal diseases between November 2018-March 2020. Thirty seven patients completed the study. Changes in MASI, pigment and erythema scores measured by mexameter before and after treatment were compared for two groups. A statistically significant decrease in MASI scores, pigment and erythema scores was observed in both groups with no significant difference between two groups. In conclusion, in our study, it has been shown that Jessner peeling and 1064 nm Q-switched Nd:YAG laser are equally effective in treatment of melasma.

Asunto(s)

RESUMEN

Platelet-rich plasma (PRP), which is widely used in many dermatologic conditions, has also been used in the treatment of melasma in recent years. The objective of this study is to determine the efficacy of PRP in melasma. Fifteen female patients with melasma participated in this study. Intradermal PRP was performed every 3 weeks for three times. We photographed all participants, performed Melasma Area and Severity Index (MASI), and measured melanin and erythema index (EI) with mexameter before every session and 1 month after the last session. Patients self-assessment of pigmentation grade (0-10) were also employed at baseline and 1 month after the last procedure. Mean MASI of the patients reduced from 10 ± 3.6 to 7.3 ± 2.5. Melanin index (MI) and EI evaluated by mexameter reduced from 256.5 ± 31 to 238.9 ± 29.9 and from 329.9 ± 53.8 to 322.7 ± 77.6, respectively. Mean patients self-assessment score (PSS) reduced from 8.3 ± 1.3 to 5 ± 1.4. Mean MASI, MI, and PSS reduction after treatment was found significant (p = .001, p = .000, p = .000). Intradermal application of PRP is an effective option for treatment of melasma. It also has other benefits like improvement in skin appearance. Because recurrence is common in melasma, depigmenting agents should be used after all procedures.

Asunto(s)

RESUMEN

PURPOSE: Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6 weeks. Omalizumab, an anti-IgE antibody that binds circulating free IgE, has recently emerged as a promising treatment for CSU, a condition which impairs patients' quality of life. We aimed to contribute real life data by reporting our experience with omalizumab in the treatment of intractable CSU. METHODS: Of 140 patients treated with omalizumab in our clinic between September 2013 and January 2018, 86 CSU patients with available current data were retrospectively evaluated in terms of sex, age, urticaria duration, urticaria activity score over 7 days (UAS7) before and after omalizumab, relapses and time to relapse, length of remission after omalizumab cessation, adverse events, and comorbidities. RESULTS: The mean age of the patients was 45.5 ± 14.3 years and 73.3% were women. Mean duration of urticaria before initiation of omalizumab therapy was 54.5 ± 67 months. All patients had used antihistamines before starting omalizumab treatment. The mean number of omalizumab doses was 11.9 ± 9.3. The mean duration of omalizumab treatment was 13.3 ± 10.4 months. Mean UAS7 score was 38.9 ± 4.1 before the start of omalizumab treatment, and 7.9 ± 10.5 after treatment. Treatment was discontinued in 10 patients (11.6%) due to nonresponse or loss of effect. Four patients (4.65%) experienced adverse events. Treatment was discontinued in 1 patient (1.16%) due to side effects. Of the 55 patients whose treatment was discontinued after their symptoms resolved, 31 (56.3%) relapsed after omalizumab cessation. Twenty-four patients (43.6%) did not relapse after omalizumab cessation. CONCLUSIONS: Our results show that omalizumab was an effective treatment for intractable CSU and did not cause any serious adverse effects other than asthenia, vertigo, and injection site reaction in four patients. These findings are relevant because they reflect real-life data.

Asunto(s)

Asunto(s)